tiprankstipranks
Eiger Biopharmaceuticals CFO Exits Amid Bankruptcy Reorganization
Company Announcements

Eiger Biopharmaceuticals CFO Exits Amid Bankruptcy Reorganization

Pick the best stocks and maximize your portfolio:

Eiger Biopharmaceuticals (EIGRQ) has provided an update.

William G. Kachioff is stepping down as Chief Financial Officer of Eiger BioPharmaceuticals, effective April 29, 2024, amidst the company’s ongoing Chapter 11 bankruptcy proceedings. Following his departure, Eiger BioPharmaceuticals is increasing its reliance on financial advisory firm Alvarez & Marsal, appointing its managing director Douglas Staut as Chief Restructuring Officer. Investors are warned that trading the company’s securities is highly speculative and risky, with the potential for significant or total investment losses, depending on the resolution of the bankruptcy case.

For an in-depth examination of EIGRQ stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskEiger BioPharmaceuticals Files for Chapter 11, Warns Investors
TipRanks Auto-Generated NewsdeskEiger BioPharmaceuticals Issues Chapter 11 Financial Update
TipRanks Auto-Generated NewsdeskEiger BioPharmaceuticals Announces Bankruptcy and Liquidation Plan
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App